May 31, 2016
The FDA has designated Cidara Therapeutics’ topical antifungal treatment as a qualified infectious disease product and granted fast track status for its development, the company announced today.
CD101 topical is used for the treatment of vulvovaginal candidiasis (VVC) and the prevention of recurrent VVC infections, the release said. The drug has previously demonstrated broad-spectrum activity against Candida species. It will be further evaluated this year in the RADIANT study — a phase 2 comparative clinical trial.